Skip to main content
Journal cover image

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.

Publication ,  Journal Article
Daughety, MM; Morgan, A; Frost, E; Kao, C; Hwang, J; Tobin, R; Patel, B; Fuller, M; Welsby, I; Ortel, TL
Published in: Thromb Res
December 2020

• COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Thromb Res

DOI

EISSN

1879-2472

Publication Date

December 2020

Volume

196

Start / End Page

483 / 485

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Treatment Outcome
  • Time Factors
  • Thrombosis
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Daughety, M. M., Morgan, A., Frost, E., Kao, C., Hwang, J., Tobin, R., … Ortel, T. L. (2020). COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res, 196, 483–485. https://doi.org/10.1016/j.thromres.2020.10.004
Daughety, Molly M., Andrew Morgan, Erin Frost, Chester Kao, Joyce Hwang, Rachel Tobin, Bhavik Patel, Matthew Fuller, Ian Welsby, and Thomas L. Ortel. “COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.Thromb Res 196 (December 2020): 483–85. https://doi.org/10.1016/j.thromres.2020.10.004.
Daughety MM, Morgan A, Frost E, Kao C, Hwang J, Tobin R, et al. COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res. 2020 Dec;196:483–5.
Daughety, Molly M., et al. “COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.Thromb Res, vol. 196, Dec. 2020, pp. 483–85. Pubmed, doi:10.1016/j.thromres.2020.10.004.
Daughety MM, Morgan A, Frost E, Kao C, Hwang J, Tobin R, Patel B, Fuller M, Welsby I, Ortel TL. COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res. 2020 Dec;196:483–485.
Journal cover image

Published In

Thromb Res

DOI

EISSN

1879-2472

Publication Date

December 2020

Volume

196

Start / End Page

483 / 485

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Treatment Outcome
  • Time Factors
  • Thrombosis
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Middle Aged
  • Male
  • Humans